Stereotaxis, Inc.(STXS)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Stereotaxis, Inc. (STXS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STXS at 18.7/100 on a 32-signal composite quality model, placing it at rank #2,804 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.1) and revenue scale (5.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Stereotaxis, Inc. reports quarterly revenue of $7.7M, net income of $-4.5M, an operating margin of -59.6%. Top institutional holders of STXS by reported 13-F value include DAFNA Capital Management, BlackRock, Lagoda Investment Management, L.P., based on the most recent SEC filings. STXS trades on the NYSE exchange and files with the SEC under CIK 1289340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stereotaxis, Inc. directly from SEC EDGAR.